Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AB Science SA initiates phase 3 study of masitinib in combination with docetaxel


Thursday, 20 Feb 2014 12:00pm EST 

AB Science SA:Announces the initiation of a phase 3 study to evaluate the safety and efficacy of masitinib in combination with docetaxel in first line treatment of metastatic Castrate Resistant Prostate Cancer (mCRPC).Says this international, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare masitinib in combination with docetaxel to placebo in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC).Says the study will measure overall survival as a primary efficacy criterion.Says the phase 3 study has been authorized by competent authorities and will recruit 550 patients.